LONDON – The UK's National Institute for Health and Care Excellence (NICE) has refused to approve payment for Roche AG's breakthrough breast cancer drug Kadcyla (trastuzumab emtansine), undermining a new voluntary pricing scheme that is intended to ensure better access to innovative drugs.